ABOUT US
Introduction
Chairman's Statement
Contact Us
R&D
R&D Platforms
R&D Capability
R&D Center
Scientific Activities
PRODUCTS
bFGF Series
other ophthalmic products
other surgical products
NEWS
company news
investee news
media focus
INVESTOR RELATIONS
Announcements & Shareholder Info
Corporate Info
Financial & ESG Reports
Contact Us
CAREERS
Talent Concept
Job Opportunities
简
繁
EN
ABOUT US
Introduction
Chairman's Statement
Contact Us
R&D
R&D Platforms
R&D Capability
R&D Center
Scientific Activities
PRODUCTS
bFGF Series
other ophthalmic products
other surgical products
NEWS
company news
investee news
media focus
INVESTOR RELATIONS
Announcements & Shareholder Info
Corporate Info
Financial & ESG Reports
Contact Us
CAREERS
Talent Concept
Job Opportunities
简
繁
EN
简
繁
EN
COMPANY NEWS
Essex Bio-Technology Included in Forbes Asia's Best Under A Billion 2020
2020.11.23
Time
Last 7 days
Last 30 days
The last six months
Date
Title
2019-01-10
The cellular growth factor project of Essex Bio-Technology Limited was honoured with the second prize of National Scientific and Technology Progress f
2018-10-30
Essex Bio-technology Entered into Convertible Notes Purchase Agreement and License Agreement with DB Therapeutics
2018-10-29
Essex Bio-Technology Announces First Patient First Visit in U.S. FDA Phase 3 Clinical Trial of SkQ1 Occurred on 27 October 2018
2018-08-22
Preservative-free Single-dose Sodium Hyaluronate Eye Drops Obtained Approval from SDA for Commercilisation in China
2018-08-10
Group Turnover and Profit in the First Half of 2018 Increased 28.3%
2018-07-24
Essex Bio-Technology Investing in Chengdu Shanggong Medical Technology Co.,Ltd., A Data Analytics Company for Diabetic Retinopathy Diagnosis
2018-07-18
Essex Bio-Technology Enters into Global Co-Development Agreement with Mitotech to Fund Phase 3 Clinical Trial in U.S. FDA of a First-In-Class Drug for Dry Eye Disease
2018-04-12
Zhuhai Essex Bio-Pharmaceutical Obtained a GMP Certificate for Preservative-Free Single-Dose Tobramycin Eye Drops
<
1
2
3
4
>
